<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-44601" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Pentobarbital</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Johnson</surname>
            <given-names>Anna B.</given-names>
          </name>
          <aff>Nova Southeastern University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sadiq</surname>
            <given-names>Nazia M.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Anna Johnson declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Nazia Sadiq declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>25</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-44601.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Pentobarbital belongs to the barbiturate class of medications and is approved by the US Food and Drug Administration (FDA)&#x000a0;for managing&#x000a0;various medical conditions such as seizures,&#x000a0;status epilepticus, and short-term treatment of insomnia.&#x000a0;At low doses, approved indications of pentobarbital include short-term sedatives to treat insomnia and as a pre-anesthetic agent for surgery in the operating room. Pentobarbital&#x000a0;primarily acts on the central nervous system (CNS).&#x000a0;At elevated doses, pentobarbital functions as an anticonvulsant for emergent seizure control and for inducing medically induced comas.&#x000a0;Studies have demonstrated the superiority of pentobarbital due to its faster brain penetration and shorter half-life, thereby making it the preferred treatment for refractory status epilepticus.</p>
        <p>Pentobarbital functions within the CNS by binding to gamma-aminobutyric acid (GABA) A subtype receptors. This action potentiates GABA effects, resulting in CNS depression and inhibiting glutamate, further leading to an additive effect on CNS depression. Although the lack of an antidote has led to decreased first-line usage of the drug, its indications remain recognized. This activity reviews the indications, mechanism of action, administration, adverse effects, and contraindications of pentobarbital therapy in the clinical setting. This activity also entails members of an interprofessional healthcare team in treating patients undergoing treatment with pentobarbital and its related conditions and sequelae, reviewing the essential pearls.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify appropriate indications for pentobarbital therapy in clinical practice in patients with various conditions, such as seizures, insomnia, and&#x000a0;status epilepticus.</p></list-item><list-item><p>Screen patients for contraindications and potential risk factors before initiating pentobarbital therapy.</p></list-item><list-item><p>Apply evidence-based guidelines and comprehensive knowledge of pentobarbital's pharmacology, pharmacokinetics, and potential drug interactions for the safe and effective use of&#x000a0;pentobarbital.</p></list-item><list-item><p>Collaborate with other healthcare professionals to ensure coordinated and comprehensive care for patients receiving pentobarbital therapy.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=44601&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=44601">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-44601.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Pentobarbital belongs to the barbiturate class of medications and primarily works primarily on the central nervous system (CNS).</p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>Pentobarbital&#x000a0;is approved by the US Food and Drug Administration (FDA)&#x000a0;for managing various medical conditions such as&#x000a0;status epilepticus, pre-anesthesia or sedation, and short-term treatment of insomnia.&#x000a0;At low doses, approved indications of pentobarbital&#x000a0;include short-term sedatives to treat insomnia and as a pre-anesthetic agent for surgery in the operating room.<xref ref-type="bibr" rid="article-44601.r1">[1]</xref> At elevated doses, pentobarbital functions as an anticonvulsant for emergent seizure control and for inducing medically induced comas.</p>
        <p>According to the American Academy of Neurology (AAN) guidelines, pentobarbital is often used for refractory status epilepticus.<xref ref-type="bibr" rid="article-44601.r2">[2]</xref>&#x000a0;Studies have demonstrated the superiority of pentobarbital due to its faster brain penetration and shorter half-life, thereby making it the preferred treatment for refractory status epilepticus.</p>
        <p><bold>Off-Label Uses</bold>&#x000a0;</p>
        <p>Common off-label uses of pentobarbital include controlling&#x000a0;intracranial pressure in patients with severe brain injuries, cerebral ischemia, and those undergoing treatment for Reye syndrome.<xref ref-type="bibr" rid="article-44601.r3">[3]</xref><xref ref-type="bibr" rid="article-44601.r4">[4]</xref>&#x000a0;Some US states use&#x000a0;pentobarbital&#x000a0;for capital punishment, but this remains controversial, and some manufacturers do not allow&#x000a0;the sale to prisons. More commonly, it is used by&#x000a0;veterinarians for euthanasia and anesthesia.<xref ref-type="bibr" rid="article-44601.r5">[5]</xref></p>
      </sec>
      <sec id="article-44601.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Pentobarbital&#x000a0;primarily acts on the central nervous system (CNS) by binding to gamma-aminobutyric acid (GABA) A subtype receptors.&#x000a0;This action induces a change in the chloride transport receptor,&#x000a0;increasing the duration the chloride channels remain open, potentiating GABA effects. GABA is responsible for producing CNS depression, prolonging the time the channels remain open, and intensifying the depressant effects on the CNS.<xref ref-type="bibr" rid="article-44601.r6">[6]</xref>&#x000a0;</p>
        <p>Pentobarbital also works by inhibiting glutamate, which is responsible for nerve depolarization in the voltage-activated calcium currents.<xref ref-type="bibr" rid="article-44601.r7">[7]</xref> This activity has an additive effect on CNS depression.&#x000a0;Although the lack of an antidote has led to decreased first-line usage of the drug, its indications remain recognized.</p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold> The onset of action of intravenous (IV) injection is immediate. CNS depression is achieved within 15 minutes. Intramuscular (IM) administration also has a rapid onset of action. Oral and rectal phenobarbital acts within 20 to 60 minutes.&#x000a0;</p>
        <p><bold>Distribution:</bold> Pentobarbital rapidly crosses the blood-brain barrier. The volume of distribution is approximately 1 L/kg.<xref ref-type="bibr" rid="article-44601.r8">[8]</xref></p>
        <p><bold>Metabolism:</bold> Pentobarbital undergoes first-pass metabolism in the liver. Pentobarbital is metabolized predominantly by the hepatic microsomal enzymes.</p>
        <p><bold>Elimination:</bold> The&#x000a0;elimination half-life of pentobarbital in adults is 15 to 50 hours and&#x000a0;is&#x000a0;dose-dependent. Metabolic end products of pentobarbital are excreted&#x000a0;predominantly via&#x000a0;urine, and a minor amount is excreted in feces.<xref ref-type="bibr" rid="article-44601.r9">[9]</xref></p>
      </sec>
      <sec id="article-44601.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Strengths</bold>
</p>
        <p>Pentobarbital administration&#x000a0;is through IM, IV, or oral routes. For&#x000a0;IM administration, injecting no more than 5 mL&#x000a0;and only into a large muscle to avoid tissue irritation or necrosis is advised.&#x000a0;IV administration should not exceed 50 mg/min and should only be given by slow IV injection in the undiluted form.<xref ref-type="bibr" rid="article-44601.r10">[10]</xref></p>
        <p>Avoiding tissue extravasation in this process is essential as it has been known to cause tissue necrosis. Clinicians should avoid rapid IV injection as it&#x000a0;may result in respiratory depression, hypotension, and bronchospasm, among other adverse effects.<xref ref-type="bibr" rid="article-44601.r8">[8]</xref>&#x000a0;The dosage should be individualized according to the clinical need, patient status, and presence of commodities.&#x000a0;</p>
        <p>
<bold>Adult Dosage</bold>
</p>
        <p><bold>Status epilepticus: </bold>Pentobarbital can be administered in refractory status epilepticus according to the AAN guidelines for convulsive status epileptics.&#x000a0;Clinicians must recognize that pentobarbital is reserved for refractory status epilepticus not responding to first or second-line treatment options.<xref ref-type="bibr" rid="article-44601.r2">[2]</xref>&#x000a0;</p>
        <p>According to Neurocritical Care Society (NCS) guidelines, the loading dose of pentobarbital is 5 to 15 mg/kg (infusion rate &#x02264;50 mg/min).&#x000a0;This loading dose is followed by a continuous infusion of 0.5 to 5 mg/kg/h. In patients&#x000a0;having breakthrough seizures, an additional dosage of 5 mg/kg bolus and an increase of infusion rate by 0.5 to 1 mg/kg/h every 12 hours is recommended.<xref ref-type="bibr" rid="article-44601.r11">[11]</xref></p>
        <p><bold>Pre-anesthesia or sedation:</bold> The dosage of pentobarbital is 150 to 200 mg administered as an IM injection.&#x000a0;</p>
        <p><bold>Insomnia: </bold>American Society of Sleep Medicine guidelines do not endorse using barbiturates for sleep onset or sleep maintenance insomnia.<xref ref-type="bibr" rid="article-44601.r12">[12]</xref></p>
        <p>
<bold>Pediatric Dosage</bold>
</p>
        <p>Oral administration can be facilitated by mixing the drug with flavored syrup to enhance palatability in pediatric populations. Although IV pentobarbital in a dosage of 2 to 6 mg/kg can be utilized for procedural sedation, alternative medications are generally preferred.<xref ref-type="bibr" rid="article-44601.r13">[13]</xref></p>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment:</bold> As clinical data regarding the use of pentobarbital in hepatic impairment are lacking, pentobarbital should be used with caution.</p>
        <p><bold>Renal impairment:&#x000a0;</bold>In cases of renal impairment, IV formulations containing propylene glycol may induce metabolic acidosis (resulting in an increased anion gap) and elevated osmolar gap. Caution is advised when using such formulations in individuals with impaired renal function.<xref ref-type="bibr" rid="article-44601.r14">[14]</xref><xref ref-type="bibr" rid="article-44601.r15">[15]</xref></p>
        <p><bold>Pregnancy considerations:&#x000a0;</bold>In considerations of pregnancy, avoidance of use is recommended, with reference to contraindications. If pentobarbital is utilized during pregnancy, patients should be duly informed about the potential risks to the fetus.<xref ref-type="bibr" rid="article-44601.r16">[16]</xref></p>
        <p><bold>Breastfeeding considerations: </bold>In breastfeeding considerations, it should be noted that barbiturates are present in breast milk. As clinical data regarding the use of pentobarbital during breastfeeding&#x000a0;are&#x000a0;lacking, it is advisable to consider alternative agents, particularly when nursing a newborn or preterm infant.<xref ref-type="bibr" rid="article-44601.r17">[17]</xref></p>
        <p><bold>Older patients: </bold>According to the American Geriatrics Society Beers Criteria<sup>&#x000ae;</sup>, barbiturates, including pentobarbital, should be used cautiously due to the risk of&#x000a0;physical dependence and increased overdose. Thus, as healthcare professionals advise, the drug should be used in low&#x000a0;doses.<xref ref-type="bibr" rid="article-44601.r18">[18]</xref></p>
      </sec>
      <sec id="article-44601.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The main adverse reactions surrounding pentobarbital use are&#x000a0;CNS effects, including altered mental status, agitation, confusion, drowsiness, respiratory depression, bradycardia, hypotension, cardiovascular collapse, and syncope. Other significant adverse effects to be aware of include hallucinations, headache, insomnia, nausea, vomiting, hepatoxicity, megaloblastic anemia, angioedema, local injection site reactions, laryngospasm, bronchospasm, apnea, and hyperkinesia.<xref ref-type="bibr" rid="article-44601.r1">[1]</xref>&#x000a0;At high doses of pentobarbital, total&#x000a0;loss of neurological function is observed.<xref ref-type="bibr" rid="article-44601.r11">[11]</xref></p>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <p>Pentobarbital interacts with several major classes of drugs and requires close monitoring to maintain therapeutic drug levels. As a class, barbiturates induce hepatic microsomal enzymes, which increase the rate of metabolism of other drugs metabolized by these hepatic enzymes. In particular, anticoagulants can be affected, and patients taking these drugs, predominantly warfarin, may require dosage adjustments. Other drug interactions to be aware of include levothyroxine, corticosteroids, doxycycline, phenytoin, valproic acid, alcohol, monoamine oxidase inhibitors (MAOIs), and some hormones such as estradiol, estrone, and progesterone.<xref ref-type="bibr" rid="article-44601.r19">[19]</xref></p>
        <p>Barbiturates can decrease the absorption of griseofulvin. Concomitant administration requires dose adjustment.<xref ref-type="bibr" rid="article-44601.r20">[20]</xref>&#x000a0;Barbiturates&#x000a0;combined&#x000a0;with CNS depressants such as benzodiazepines and opioids can&#x000a0;lead to&#x000a0;profound&#x000a0;respiratory&#x000a0;depression.<xref ref-type="bibr" rid="article-44601.r21">[21]</xref><xref ref-type="bibr" rid="article-44601.r22">[22]</xref>&#x000a0;Misusing kratom with barbiturates can lead to severe CNS depression and death.<xref ref-type="bibr" rid="article-44601.r23">[23]</xref></p>
      </sec>
      <sec id="article-44601.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Contraindications to pentobarbital use include prior hypersensitivity reactions to drug use or barbiturate class use.&#x000a0;Barbiturates can trigger&#x000a0;hypersensitivity reactions by direct histamine release or immunoglobulin E (IgE)&#x02013;mediated mechanisms and can lead to anaphylaxis.<xref ref-type="bibr" rid="article-44601.r24">[24]</xref>&#x000a0;Other contraindications include patients with depressed respiratory function and porphyria. Abrupt drug withdrawal in patients on long-term pentobarbital&#x000a0;therapy should be avoided.&#x000a0;Clinical staff should exercise caution using this drug in older patients, those with renal impairment, hepatic impairment, and those with a drug misuse history.<xref ref-type="bibr" rid="article-44601.r18">[18]</xref></p>
        <p>Barbiturates are pregnancy category D drugs and have been shown to cause fetal damage if used in pregnant&#x000a0;patients. This class of drugs can cross the placental barrier and distribute throughout the fetal tissue with the highest concentrations in the liver, brain, and placenta. Monitoring maternal blood levels for fetal safety in any pregnant&#x000a0;patient taking these drugs is essential.</p>
        <p>Documented evidence of withdrawal exists in infants born to mothers who took barbiturates during pregnancy. Newborns should be closely monitored for seizures and hyperirritability, which may indicate a need for withdrawal treatment. Symptoms can be delayed for up to&#x000a0;2 weeks and require prompt treatment if indicated.<xref ref-type="bibr" rid="article-44601.r25">[25]</xref></p>
      </sec>
      <sec id="article-44601.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Toxic doses of pentobarbital occur at approximately 1&#x000a0;g in most adults, with death occurring at 2 to 10 g. The therapeutic&#x000a0;concentration&#x000a0;of pentobarbital depends on the intended therapeutic effect. The sedation&#x000a0;dose is 1 to 5 mcg/mL. For intracranial pressure therapy, the recommended dose is 30 to 40 mcg/mL, while for therapeutic coma, it is 20 to 50 mcg/mL. Sedation is considered toxic at values exceeding 10 mcg/mL. The time to reach a steady state in adults is typically 3 to 6 days. Monitoring parameters include electroencephalogram (EEG) and serum drug levels. Other things to consider when assessing for toxicity are a complete blood count (CBC), liver function tests (LFTs), and a blood urea nitrogen (BUN) to creatinine ratio if on continuous treatment.&#x000a0;</p>
        <p>Pentobarbital is a high-risk habit-forming drug categorized&#x000a0;by the Federal Controlled Substances Act under DEA Schedule II. Tolerance, physical dependence, and psychological effects can occur in patients with long-term use. Estimates are that the threshold for developing dependence is over 400 mg daily for over 90 days. In addition, dosages of 600 to 800 mg daily for&#x000a0;more than 35 days correlate with withdrawal seizures.</p>
        <p>Symptoms of acute intoxication include gait and speech alterations and neurological manifestations. Chronic intoxication demonstrates confusion, agitation, insomnia, and generalized myalgias. Minor withdrawal is seen within 8 to 12 hours, and significant withdrawal within 16 hours, lasting for up to&#x000a0;1 week following cessation of the drug. Treatment of dependence includes close monitoring and gradual withdrawal of the drug by small dosage decreases over many weeks&#x02014;infants&#x000a0;with physical dependence commonly present with hyperactivity, sleep disturbances, and hyperreflexia. Treatment of withdrawal in this population usually spans over&#x000a0;2 weeks.<xref ref-type="bibr" rid="article-44601.r26">[26]</xref></p>
        <p>According to AAN guidelines on convulsive status epilepticus, EEG monitoring is required when administering pentobarbital.<xref ref-type="bibr" rid="article-44601.r2">[2]</xref>&#x000a0;Clinicians must be aware that pentobarbital is often confused with phenobarbital, a different drug with differing&#x000a0;dosages and a similar mechanism of action.</p>
      </sec>
      <sec id="article-44601.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Pediatric neurotoxicity&#x000a0;is reported with the use of pentobarbital. Barbiturates,&#x000a0;including pentobarbital, can increase&#x000a0;GABA activity,&#x000a0;leading to increased neuronal apoptosis and impaired cognition when used for more than 3 hours.<xref ref-type="bibr" rid="article-44601.r27">[27]</xref>&#x000a0;Treatment of pentobarbital toxicity involves supportive care, as no antidote exists. Overdose can lead to airway compromise, cardiovascular collapse, coma, and death. Treatment often requires intubation, hemodynamic support with vasopressors, and maintaining body temperature with warmers, commonly in an intensive care unit (ICU) setting. In mild or early cases of toxicity, activated charcoal and alkaline diuresis have been added but show minimal benefits. Always contact poison control if poisoning or overdose is suspected.</p>
        <p>Caution is warranted for individuals with renal and hepatic impairment. While the manufacturer does not offer specific dosage adjustment recommendations for renal impairment, monitoring kidney function when administering high doses or conducting prolonged treatment is crucial. Comparable effects are observed in individuals with hepatic impairment, necessitating close patient monitoring. Continuous venovenous hemofiltration is known to enhance the removal of pentobarbital.<xref ref-type="bibr" rid="article-44601.r28">[28]</xref></p>
      </sec>
      <sec id="article-44601.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Pentobarbital is not used widely in clinical medicine because of its poor safety profile, habituation, and lack of an antidote. All prescribing clinicians should be aware of&#x000a0;the drug's toxicity and&#x000a0;adverse&#x000a0;event profile. Neurologists can use pentobarbital for refractory status epilepticus.<xref ref-type="bibr" rid="article-44601.r2">[2]</xref>&#x000a0;Withdrawal from pentobarbital can be life-threatening. Managing pentobarbital withdrawal requires a well-trained interprofessional healthcare team, including nurses, pharmacists, and several&#x000a0;clinicians from different specialties. Without proper management, the morbidity and mortality from unrecognized pentobarbital withdrawal are high.</p>
        <p>Properly treating pentobarbital withdrawal begins when a&#x000a0;clinician recognizes the patient is either susceptible to or suffering from withdrawal. When withdrawal is suspected, the interprofessional team must coordinate patient care by:</p>
        <list list-type="bullet">
          <list-item>
            <p>Obtaining a thorough history and physical examinations.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Ordering drug levels in the blood or urine, appropriate laboratory tests, and imaging in the emergency department.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Monitoring the patient for signs and symptoms of respiratory depression, cardiovascular collapse,&#x000a0;CNS dysfunction, and renal or hepatic toxicity.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Preparing to provide airway protection and vasopressor support if indicated.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Consulting with the pharmacist about drug interactions if the patient is taking other medications.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Consulting with a medical toxicologist.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Consulting with the intensivist about ICU care and monitoring during hospitalization.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Considering long-term management with social work to provide outpatient follow-up.</p>
          </list-item>
        </list>
        <p>To avoid the high potential for morbidity and mortality associated with pentobarbital, the pharmacist should recommend prescribing clinicians safer alternative agents. Nurses should monitor the patient at subsequent visits, verifying medication compliance and treatment effectiveness. With an interprofessional team approach&#x000a0;of clinicians&#x000a0;and specialists, toxicologists, and pharmacists, utilizing open communication and shared decision-making, the morbidity of pentobarbital can be reduced and clinical success optimized.</p>
      </sec>
      <sec id="article-44601.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=44601&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=44601">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/44601/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=44601">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-44601.s11">
        <title>References</title>
        <ref id="article-44601.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abou Khaled</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Hirsch</surname>
                <given-names>LJ</given-names>
              </name>
            </person-group>
            <article-title>Updates in the management of seizures and status epilepticus in critically ill patients.</article-title>
            <source>Neurol Clin</source>
            <year>2008</year>
            <month>May</month>
            <volume>26</volume>
            <issue>2</issue>
            <fpage>385</fpage>
            <page-range>385-408, viii</page-range>
            <pub-id pub-id-type="pmid">18514819</pub-id>
          </element-citation>
        </ref>
        <ref id="article-44601.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Glauser</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Shinnar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gloss</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Alldredge</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Arya</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bainbridge</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bare</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bleck</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Dodson</surname>
                <given-names>WE</given-names>
              </name>
              <name>
                <surname>Garrity</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Jagoda</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lowenstein</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Pellock</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Riviello</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sloan</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Treiman</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>Evidence-Based Guideline: Treatment of Convulsive Status Epilepticus in Children and Adults: Report of the Guideline Committee of the American Epilepsy Society.</article-title>
            <source>Epilepsy Curr</source>
            <year>2016</year>
            <season>Jan-Feb</season>
            <volume>16</volume>
            <issue>1</issue>
            <fpage>48</fpage>
            <page-range>48-61</page-range>
            <pub-id pub-id-type="pmid">26900382</pub-id>
          </element-citation>
        </ref>
        <ref id="article-44601.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Adelson</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Bratton</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Carney</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Chesnut</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>du Coudray</surname>
                <given-names>HE</given-names>
              </name>
              <name>
                <surname>Goldstein</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kochanek</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Partington</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Selden</surname>
                <given-names>NR</given-names>
              </name>
              <name>
                <surname>Warden</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Wright</surname>
                <given-names>DW</given-names>
              </name>
              <collab>American Association for Surgery of Trauma</collab>
              <collab>Child Neurology Society</collab>
              <collab>International Society for Pediatric Neurosurgery</collab>
              <collab>International Trauma Anesthesia and Critical Care Society</collab>
              <collab>Society of Critical Care Medicine</collab>
              <collab>World Federation of Pediatric Intensive and Critical Care Societies</collab>
            </person-group>
            <article-title>Guidelines for the acute medical management of severe traumatic brain injury in infants, children, and adolescents. Chapter 13. The use of barbiturates in the control of intracranial hypertension in severe pediatric traumatic brain injury.</article-title>
            <source>Pediatr Crit Care Med</source>
            <year>2003</year>
            <month>Jul</month>
            <volume>4</volume>
            <issue>3 Suppl</issue>
            <fpage>S49</fpage>
            <page-range>S49-52</page-range>
            <pub-id pub-id-type="pmid">12847349</pub-id>
          </element-citation>
        </ref>
        <ref id="article-44601.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bernstein</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Ghanchi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kashyap</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Podkovik</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Miulli</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Wacker</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Sweiss</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Pentobarbital Coma With Therapeutic Hypothermia for Treatment of Refractory Intracranial Hypertension in Traumatic Brain Injury Patients: A Single Institution Experience.</article-title>
            <source>Cureus</source>
            <year>2020</year>
            <month>Sep</month>
            <day>22</day>
            <volume>12</volume>
            <issue>9</issue>
            <fpage>e10591</fpage>
            <pub-id pub-id-type="pmid">33110727</pub-id>
          </element-citation>
        </ref>
        <ref id="article-44601.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Holtkamp</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Masuhr</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Harms</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Einh&#x000e4;upl</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Meierkord</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Buchheim</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>The management of refractory generalised convulsive and complex partial status epilepticus in three European countries: a survey among epileptologists and critical care neurologists.</article-title>
            <source>J Neurol Neurosurg Psychiatry</source>
            <year>2003</year>
            <month>Aug</month>
            <volume>74</volume>
            <issue>8</issue>
            <fpage>1095</fpage>
            <page-range>1095-9</page-range>
            <pub-id pub-id-type="pmid">12876241</pub-id>
          </element-citation>
        </ref>
        <ref id="article-44601.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Walker</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Iazzetta</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Compatibility and stability of pentobarbital ininfusions.</article-title>
            <source>Anesthesiology</source>
            <year>1981</year>
            <month>Oct</month>
            <volume>55</volume>
            <issue>4</issue>
            <fpage>487</fpage>
            <page-range>487-9</page-range>
            <pub-id pub-id-type="pmid">7294399</pub-id>
          </element-citation>
        </ref>
        <ref id="article-44601.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wermeling</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Blouin</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Porter</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Rapp</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Tibbs</surname>
                <given-names>PA</given-names>
              </name>
            </person-group>
            <article-title>Pentobarbital pharmacokinetics in patients with severe head injury.</article-title>
            <source>Drug Intell Clin Pharm</source>
            <year>1987</year>
            <month>May</month>
            <volume>21</volume>
            <issue>5</issue>
            <fpage>459</fpage>
            <page-range>459-63</page-range>
            <pub-id pub-id-type="pmid">3582175</pub-id>
          </element-citation>
        </ref>
        <ref id="article-44601.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ehrnebo</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics and distribution properties of pentobarbital in humans following oral and intravenous administration.</article-title>
            <source>J Pharm Sci</source>
            <year>1974</year>
            <month>Jul</month>
            <volume>63</volume>
            <issue>7</issue>
            <fpage>1114</fpage>
            <page-range>1114-8</page-range>
            <pub-id pub-id-type="pmid">4853598</pub-id>
          </element-citation>
        </ref>
        <ref id="article-44601.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zuppa</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Nicolson</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Barrett</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Gastonguay</surname>
                <given-names>MR</given-names>
              </name>
            </person-group>
            <article-title>Population pharmacokinetics of pentobarbital in neonates, infants, and children after open heart surgery.</article-title>
            <source>J Pediatr</source>
            <year>2011</year>
            <month>Sep</month>
            <volume>159</volume>
            <issue>3</issue>
            <fpage>414</fpage>
            <page-range>414-419.e1-3</page-range>
            <pub-id pub-id-type="pmid">21665222</pub-id>
          </element-citation>
        </ref>
        <ref id="article-44601.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Knodell</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Spector</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Brooks</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Keller</surname>
                <given-names>FX</given-names>
              </name>
              <name>
                <surname>Kyner</surname>
                <given-names>WT</given-names>
              </name>
            </person-group>
            <article-title>Alterations in pentobarbital pharmacokinetics in response to parenteral and enteral alimentation in the rat.</article-title>
            <source>Gastroenterology</source>
            <year>1980</year>
            <month>Dec</month>
            <volume>79</volume>
            <issue>6</issue>
            <fpage>1211</fpage>
            <page-range>1211-6</page-range>
            <pub-id pub-id-type="pmid">6777235</pub-id>
          </element-citation>
        </ref>
        <ref id="article-44601.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brophy</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Bell</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Claassen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Alldredge</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bleck</surname>
                <given-names>TP</given-names>
              </name>
              <name>
                <surname>Glauser</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Laroche</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Riviello</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Shutter</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Sperling</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Treiman</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Vespa</surname>
                <given-names>PM</given-names>
              </name>
              <collab>Neurocritical Care Society Status Epilepticus Guideline Writing Committee</collab>
            </person-group>
            <article-title>Guidelines for the evaluation and management of status epilepticus.</article-title>
            <source>Neurocrit Care</source>
            <year>2012</year>
            <month>Aug</month>
            <volume>17</volume>
            <issue>1</issue>
            <fpage>3</fpage>
            <page-range>3-23</page-range>
            <pub-id pub-id-type="pmid">22528274</pub-id>
          </element-citation>
        </ref>
        <ref id="article-44601.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sateia</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Buysse</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Krystal</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Neubauer</surname>
                <given-names>DN</given-names>
              </name>
              <name>
                <surname>Heald</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline.</article-title>
            <source>J Clin Sleep Med</source>
            <year>2017</year>
            <month>Feb</month>
            <day>15</day>
            <volume>13</volume>
            <issue>2</issue>
            <fpage>307</fpage>
            <page-range>307-349</page-range>
            <pub-id pub-id-type="pmid">27998379</pub-id>
          </element-citation>
        </ref>
        <ref id="article-44601.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mason</surname>
                <given-names>KP</given-names>
              </name>
              <name>
                <surname>Zurakowski</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Connor</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Karian</surname>
                <given-names>VE</given-names>
              </name>
              <name>
                <surname>Fontaine</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Sanborn</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Burrows</surname>
                <given-names>PE</given-names>
              </name>
            </person-group>
            <article-title>Infant sedation for MR imaging and CT: oral versus intravenous pentobarbital.</article-title>
            <source>Radiology</source>
            <year>2004</year>
            <month>Dec</month>
            <volume>233</volume>
            <issue>3</issue>
            <fpage>723</fpage>
            <page-range>723-8</page-range>
            <pub-id pub-id-type="pmid">15516603</pub-id>
          </element-citation>
        </ref>
        <ref id="article-44601.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kraut</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Xing</surname>
                <given-names>SX</given-names>
              </name>
            </person-group>
            <article-title>Approach to the evaluation of a patient with an increased serum osmolal gap and high-anion-gap metabolic acidosis.</article-title>
            <source>Am J Kidney Dis</source>
            <year>2011</year>
            <month>Sep</month>
            <volume>58</volume>
            <issue>3</issue>
            <fpage>480</fpage>
            <page-range>480-4</page-range>
            <pub-id pub-id-type="pmid">21794966</pub-id>
          </element-citation>
        </ref>
        <ref id="article-44601.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Greene</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Krasowski</surname>
                <given-names>MD</given-names>
              </name>
            </person-group>
            <article-title>Correlation of osmolal gap with measured concentrations of acetone, ethylene glycol, isopropanol, methanol, and propylene glycol in patients at an academic medical center.</article-title>
            <source>Toxicol Rep</source>
            <year>2020</year>
            <volume>7</volume>
            <fpage>81</fpage>
            <page-range>81-88</page-range>
            <pub-id pub-id-type="pmid">31908969</pub-id>
          </element-citation>
        </ref>
        <ref id="article-44601.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pernia</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>DeMaagd</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>The New Pregnancy and Lactation Labeling Rule.</article-title>
            <source>P T</source>
            <year>2016</year>
            <month>Nov</month>
            <volume>41</volume>
            <issue>11</issue>
            <fpage>713</fpage>
            <page-range>713-715</page-range>
            <pub-id pub-id-type="pmid">27904304</pub-id>
          </element-citation>
        </ref>
        <ref id="article-44601.r17">
          <label>17</label>
          <element-citation publication-type="book">
            <chapter-title>Pentobarbital</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2023</year>
            <month>2</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">30000440</pub-id>
          </element-citation>
        </ref>
        <ref id="article-44601.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <collab>By the 2019 American Geriatrics Society Beers Criteria&#x000ae; Update Expert Panel</collab>
            <article-title>American Geriatrics Society 2019 Updated AGS Beers Criteria&#x000ae; for Potentially Inappropriate Medication Use in Older Adults.</article-title>
            <source>J Am Geriatr Soc</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>67</volume>
            <issue>4</issue>
            <fpage>674</fpage>
            <page-range>674-694</page-range>
            <pub-id pub-id-type="pmid">30693946</pub-id>
          </element-citation>
        </ref>
        <ref id="article-44601.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Singh</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Survival after fatal pentobarbital ingestion.</article-title>
            <source>Indian J Anaesth</source>
            <year>2014</year>
            <month>Jan</month>
            <volume>58</volume>
            <issue>1</issue>
            <fpage>85</fpage>
            <page-range>85-6</page-range>
            <pub-id pub-id-type="pmid">24700912</pub-id>
          </element-citation>
        </ref>
        <ref id="article-44601.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Perucca</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Clinically relevant drug interactions with antiepileptic drugs.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>2006</year>
            <month>Mar</month>
            <volume>61</volume>
            <issue>3</issue>
            <fpage>246</fpage>
            <page-range>246-55</page-range>
            <pub-id pub-id-type="pmid">16487217</pub-id>
          </element-citation>
        </ref>
        <ref id="article-44601.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abrahamsson</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Berge</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>&#x000d6;jehagen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>H&#x000e5;kansson</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Benzodiazepine, z-drug and pregabalin prescriptions and mortality among patients in opioid maintenance treatment-A nation-wide register-based open cohort study.</article-title>
            <source>Drug Alcohol Depend</source>
            <year>2017</year>
            <month>May</month>
            <day>01</day>
            <volume>174</volume>
            <fpage>58</fpage>
            <page-range>58-64</page-range>
            <pub-id pub-id-type="pmid">28315808</pub-id>
          </element-citation>
        </ref>
        <ref id="article-44601.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Webster</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Karan</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>The Physiology and Maintenance of Respiration: A Narrative Review.</article-title>
            <source>Pain Ther</source>
            <year>2020</year>
            <month>Dec</month>
            <volume>9</volume>
            <issue>2</issue>
            <fpage>467</fpage>
            <page-range>467-486</page-range>
            <pub-id pub-id-type="pmid">33021707</pub-id>
          </element-citation>
        </ref>
        <ref id="article-44601.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gershman</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Timm</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Frank</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lampi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Melamed</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gerona</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Monte</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>Deaths in Colorado Attributed to Kratom.</article-title>
            <source>N Engl J Med</source>
            <year>2019</year>
            <month>Jan</month>
            <day>03</day>
            <volume>380</volume>
            <issue>1</issue>
            <fpage>97</fpage>
            <page-range>97-98</page-range>
            <pub-id pub-id-type="pmid">30601742</pub-id>
          </element-citation>
        </ref>
        <ref id="article-44601.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Monta&#x000f1;ez</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Mayorga</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bogas</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Barrionuevo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Fernandez-Santamaria</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Martin-Serrano</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Laguna</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Torres</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Fernandez</surname>
                <given-names>TD</given-names>
              </name>
              <name>
                <surname>Do&#x000f1;a</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology, Mechanisms, and Diagnosis of Drug-Induced Anaphylaxis.</article-title>
            <source>Front Immunol</source>
            <year>2017</year>
            <volume>8</volume>
            <fpage>614</fpage>
            <pub-id pub-id-type="pmid">28611774</pub-id>
          </element-citation>
        </ref>
        <ref id="article-44601.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ashtarinezhad</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Panahyab</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shaterzadeh-Oskouei</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Khoshniat</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Mohamadzadehasl</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Shirazi</surname>
                <given-names>FH</given-names>
              </name>
            </person-group>
            <article-title>Teratogenic study of phenobarbital and levamisole on mouse fetus liver tissue using biospectroscopy.</article-title>
            <source>J Pharm Biomed Anal</source>
            <year>2016</year>
            <month>Sep</month>
            <day>05</day>
            <volume>128</volume>
            <fpage>174</fpage>
            <page-range>174-183</page-range>
            <pub-id pub-id-type="pmid">27262993</pub-id>
          </element-citation>
        </ref>
        <ref id="article-44601.r26">
          <label>26</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Preuss</surname>
                <given-names>CV</given-names>
              </name>
              <name>
                <surname>Kalava</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>King</surname>
                <given-names>KC</given-names>
              </name>
            </person-group>
            <chapter-title>Prescription of Controlled Substances: Benefits and Risks</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>4</month>
            <day>29</day>
            <pub-id pub-id-type="pmid">30726003</pub-id>
          </element-citation>
        </ref>
        <ref id="article-44601.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Olney</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Wozniak</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Jevtovic-Todorovic</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Farber</surname>
                <given-names>NB</given-names>
              </name>
              <name>
                <surname>Bittigau</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ikonomidou</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Drug-induced apoptotic neurodegeneration in the developing brain.</article-title>
            <source>Brain Pathol</source>
            <year>2002</year>
            <month>Oct</month>
            <volume>12</volume>
            <issue>4</issue>
            <fpage>488</fpage>
            <page-range>488-98</page-range>
            <pub-id pub-id-type="pmid">12408236</pub-id>
          </element-citation>
        </ref>
        <ref id="article-44601.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hensler</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>McConnell</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Levasseur-Franklin</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Greathouse</surname>
                <given-names>KM</given-names>
              </name>
            </person-group>
            <article-title>Pentobarbital Removal During Continuous Venovenous Hemofiltration: Case Report and Review of the Literature.</article-title>
            <source>J Pharm Pract</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>31</volume>
            <issue>6</issue>
            <fpage>682</fpage>
            <page-range>682-686</page-range>
            <pub-id pub-id-type="pmid">29162023</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
